Why SCOPE 2026 Felt Different for Clinical Research

By Nicole Brenna, US Business Development Director at Cromos Pharma 

As the 17th annual SCOPE Summit wrapped up, the energy around clinical research was unmistakable. Over four days, sponsors, CROs, sites, and technology leaders came together, offering a clear view of where the industry is heading next. Compared to last year, the mood felt more optimistic, with budgets reopening and teams shifting back toward growth.  

From my perspective as a business development director, several operational, technological, and strategic themes stood out at SCOPE 2026, and they are already reshaping how clinical trials are designed and executed. 

Digital Protocols: Designing Trials for Efficiency 

Digital protocols were a recurring theme at SCOPE 2026. What was once discussed in theory is now being implemented in practice. Standards such as CDISC’s USDM are enabling protocols to move from static documents to structured, machine-readable frameworks that support feasibility, study build, and execution. 

In practice, digital protocols can automatically populate study databases, configure EDC forms, and inform feasibility assessments. Several case studies showed that when medical, operational, and regulatory teams collaborate around a single digital protocol from the start, studies see fewer amendments, less rework, and smoother execution. For CROs and sponsors, this shift is enabling faster, more predictable trial execution. 

AI in Clinical Trials: From Hype to Real Impact 

AI was everywhere at SCOPE 2026, but the conversation clearly moved beyond hype. The focus has shifted from if AI will change clinical research to how fast it can be applied in real workflows. 

Across the conference, I saw practical examples of AI already making an impact, from tools that support investigator oversight and flag critical patient data, to solutions that reduce site workload and help sponsors identify trends earlier. AI in clinical trials has matured into a usable, production-ready toolset, supporting faster trials and better real-time decision-making. 

What’s most encouraging is that the industry is moving from proof-of-concept to real deployment, using AI to streamline operations and improve outcomes, not just to experiment. 

Site Enablement: Reducing Burden and Elevating Site Voices 

Another encouraging shift at SCOPE 2026 was the stronger presence of research sites in industry discussions. Site enablement was recognized as a priority, not an afterthought. 

Across sessions and the exhibit floor, the emphasis was on reducing site burden through practical solutions: centralized site portals, single sign-on access for trial systems, and smarter scheduling tools that cut administrative overhead. This focus was further reinforced by the Site Innovation Award, which highlighted real, site-driven improvements that make trials easier to run. 

The takeaway was clear: when sponsors, CROs, and technology partners co-create solutions with site input, trials run more smoothly. Empowered sites lead to faster startup, better execution, and better outcomes for everyone involved. 

Patient Recruitment: From Campaigns to Continuous Engagement 

Patient recruitment remains one of the toughest challenges in clinical research, but SCOPE 2026 showed that the approach is clearly evolving. Instead of one-off campaigns, sponsors are increasingly treating recruitment as a continuous, technology-enabled process. 

Many are investing in platform-based recruitment models that centralize referrals, prescreening, and engagement tracking across studies. Several demos highlighted platforms that integrate with EHRs and digital channels, automatically match patients to protocol criteria, and guide them through eConsent and screening. 

The key advantage is adaptability. When eligibility criteria change or a channel underperforms, teams can adjust quickly using real-time data, something static recruitment campaigns simply can’t offer. This shift positions recruitment as a core operational capability for sponsors and CROs, while also supporting a more patient-centric experience and faster access to trials. 

Navigating an Evolving Regulatory Landscape 

Alongside innovation, regulatory uncertainty was a recurring theme at SCOPE 2026. As decentralized models, real-world evidence, and AI adoption accelerate, regulatory guidance continues to evolve. 

Sponsors repeatedly emphasized the importance of regulatory readiness, not just adopting new approaches, but being able to defend them. Discussions touched on the impact of upcoming FDA guidance, global data privacy requirements, and the need for contingency planning when expectations shift. 

A clear message emerged: innovation must move in tandem with regulatory strategy. Early dialogue with regulators, flexible trial design, and built-in alternatives are becoming essential to avoid delays and keep programs on track. 

Shaping the Future of Clinical Research 

SCOPE 2026 reinforced that the future of clinical research is already taking shape. AI is being operationalized, digital trial design is becoming standard, and patient and site perspectives are influencing how studies are built from the start. 

At Cromos Pharma, we see these shifts as an opportunity to deliver more efficient, resilient, and patient-centered trials. By combining innovation with collaboration, regulatory awareness, and operational discipline, we help sponsors navigate complexity and move faster with confidence. 

The tools are here. The expertise is here. By working together and keeping patients at the center, we can turn today’s momentum into meaningful progress for clinical research.